Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.
News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Personalis, Inc. (NASDAQ: PSNL) has announced that it will release its first quarter 2023 financial results on May 3, 2023. A conference call and webcast will follow at 2:00 p.m. Pacific Time to discuss the financial outcomes and company milestones. Interested parties can access the call via phone or through the company's website. Personalis specializes in advanced genomics aimed at improving cancer management through personalized testing and highly sensitive assays.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has announced its participation in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference. This event is scheduled for Wednesday, April 19 at 3:00 p.m. Eastern Time. The company focuses on transforming cancer management through personalized testing, offering assays that combine tumor profiling with proprietary algorithms for advanced patient insights. Their products aim to detect minimal residual disease and optimize targeted therapies based on comprehensive genomic profiling. Personalis is based in Fremont, California.
Personalis has partnered with Cancer Research UK's Cancer Research Horizons, University College London, and the Francis Crick Institute to utilize its NeXT Personal liquid biopsy assay in the TRACERx study, aiming to improve early detection of lung cancer recurrence after surgery. The NeXT Personal assay offers high sensitivity in identifying circulating tumor DNA (ctDNA) in blood samples, enabling earlier detection of residual disease. This collaboration seeks to enhance patient care by tracking minimal residual disease (MRD) and providing insights for more informed treatment decisions in lung cancer patients.
Personalis (Nasdaq: PSNL) has presented new research at the AACR Annual Meeting 2023 highlighting its advanced cancer monitoring technologies. Key findings demonstrate the effectiveness of NeXT Personal® in detecting circulating tumor DNA (ctDNA), offering the potential for earlier therapy response prediction compared to imaging methods.
Collaborating with University Medical Center Hamburg-Eppendorf, the company aims to support the routine clinical use of minimal residual disease (MRD) detection in immunotherapy. Initial results indicate enhanced survival rates linked to ctDNA clearance in melanoma patients, showcasing the platform's high sensitivity and accuracy.